ES2064391T3 - Adn que codifica un polipeptido anticoagulante. - Google Patents

Adn que codifica un polipeptido anticoagulante.

Info

Publication number
ES2064391T3
ES2064391T3 ES89113261T ES89113261T ES2064391T3 ES 2064391 T3 ES2064391 T3 ES 2064391T3 ES 89113261 T ES89113261 T ES 89113261T ES 89113261 T ES89113261 T ES 89113261T ES 2064391 T3 ES2064391 T3 ES 2064391T3
Authority
ES
Spain
Prior art keywords
polypeptide
cpbii
placent
human
dna fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89113261T
Other languages
English (en)
Inventor
Akio Iwasaki
Makoto C O Kowa Co Ltd Suda
Yushi Saino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Application granted granted Critical
Publication of ES2064391T3 publication Critical patent/ES2064391T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN POLIPEPTIDO TENIENDO UNA CADENA DE AMINOACIDOS COMO MUESTRA LA FIGURA 1 Y SU METODO DE PREPARACION SON PRESENTADOS. UN FRAGMENTO DE DNA CAPAZ DE CODIFICAR EL POLIPEPTIDO CPBII (INHIBIDOR DE LA COAGULACION DERIVADO DE LA PLACENTA HUMANA) ES OBTENIDO PRIMERO UN LIBRADOR CDNA DE LA PLACENTA HUMANA USANDO EL ANTICUERPO CPBII-ESPECIFICO COMO UNA SONDA. ENTONCES, LAS CELULAS DE LOS MICROORGANISMOS SON TRANSFORMADOS MEDIANTE EL USO DE UN PLASMIDO RECOMBINANTE INCORPORADO AL FRAGMENTO DE DNA, PERMITIENDO QUE EL TRANSFORMANTE RESULTANTE EXPRESE EL GEN CPBII, PARA FINALMENTE OBTENER UN POLIPEPTIDO SEMEJANTE AL CPBII. EL POLIPEPTIDO DE ESTA INVENCION PRESENTA FUERTES ACTIVIDADES ANTICOAGULANTES Y ES UTIL COMO COMPONENTE ACTIVO DE MEDICINAS ANTICOAGULANTES.
ES89113261T 1988-07-21 1989-07-19 Adn que codifica un polipeptido anticoagulante. Expired - Lifetime ES2064391T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63182633A JP2701047B2 (ja) 1988-07-21 1988-07-21 抗血液凝固作用を有するポリペプチド

Publications (1)

Publication Number Publication Date
ES2064391T3 true ES2064391T3 (es) 1995-02-01

Family

ID=16121703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89113261T Expired - Lifetime ES2064391T3 (es) 1988-07-21 1989-07-19 Adn que codifica un polipeptido anticoagulante.

Country Status (6)

Country Link
EP (1) EP0351826B1 (es)
JP (1) JP2701047B2 (es)
KR (1) KR970005913B1 (es)
CA (1) CA1338401C (es)
DE (1) DE68918519T2 (es)
ES (1) ES2064391T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
KR20100020236A (ko) * 2008-08-12 2010-02-22 세기 리미티드 센서를 구비한 차량용 무선통신장치 및 차량 제어시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764878B2 (ja) * 1986-10-14 1995-07-12 興和株式会社 抗血液凝固物質及びその製法

Also Published As

Publication number Publication date
DE68918519D1 (de) 1994-11-03
CA1338401C (en) 1996-06-18
EP0351826A2 (en) 1990-01-24
JP2701047B2 (ja) 1998-01-21
EP0351826A3 (en) 1990-05-23
EP0351826B1 (en) 1994-09-28
JPH0232099A (ja) 1990-02-01
KR900001847A (ko) 1990-02-27
KR970005913B1 (ko) 1997-04-22
DE68918519T2 (de) 1995-05-11

Similar Documents

Publication Publication Date Title
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
AR008555A1 (es) Constructo de acido nucleico para expresar sustancias activas que son activadas por una enzima que es liberada por celulas de mamifero, unprocedimiento para preparar un constructo de acido nucleico, el uso para preparar su farmaco, una celula alterada por medios recombinantes y una
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
DE69924615D1 (de) Thymosin beta 4 stimuliert wundheilung
ES2115662T3 (es) Modificacion genetica de celulas endoteliales.
ES2053758T3 (es) Una nueva molecula polipeptidica.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
AR012034A1 (es) ANALOGO DE FACTOR X, DNA RECOMBINANTE QUE CODIFICA PARA DICHO ANALOGO DE FACTOR X Y SU USO, COMPOSICION QUE CONTIENE ANALOGO DE FACTOR X O UNA PROTEINAPRECURSORA DEL MISMO Y SU USO, PROCEDIMIENTO DE PREPARACION DE UNA COMPOSICION CONTENIENDO ANALOGO DE FACTOR X O ANALOGO DE FACTOR Xa O FACTOR Xa ACT
AR058982A1 (es) Vector de expresion de la proteina bicunina y metodo para producir dicha proteina
MC2144A1 (fr) Peptides therapeutiques
ES2073735T3 (es) Nuevos analogos de la cadena b del factor de crecimiento derivado de plaquetas y metodo para su produccion homogenea.
ES2144394T3 (es) Polipeptidos y peptidos recombinantes, acidos nucleicos que los codifican y utilizacion de dichos polipeptidos y peptidos para el diagnostico de la tuberculosis.
ATE131532T1 (de) Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen
ATE191922T1 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
ES2064391T3 (es) Adn que codifica un polipeptido anticoagulante.
DK175989D0 (da) Fremgangsmaade til fremstilling af protein
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
ES2013500A6 (es) Metodo para producir una variante de secuencioa de aminoacidos de un activador de plasmionogeno.
WO2002050111A3 (en) Isolated laminin 10
AR247919A1 (es) Endo-1, 4-beta-glucanasa y secuencia de adn
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
BR9908096A (pt) Proteìna 3 da zona pelúcida humana (hzp3), ativa, recombinante
ES2056787T3 (es) Factor angiogenico de placenta humana capaz de estimular la sintesis capilar de proteasa de celulas endoteliales, la sintesis de adn y la migracion.
Marx A New Wave of Enzymes for Cleaving Prohormones: Researchers have isolated several enzymes that snip peptide hormones from the inactive prohormones. Some may not stand the test of time
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 351826

Country of ref document: ES